Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Mouse B7-H3 induces antitumor immunity

Abstract

Members of the B7 family costimulate the proliferation of lymphocytes during the initiation and maintenance of antigen-specific humoral and cell-mediated immune responses. While B7-1 and -2 are restricted to lymphoid tissues, and activate naïve T cells, recently identified members including B7-H2 and -H3 are widely expressed on nonlymphoid tissues, and regulate effector lymphocytes in the periphery. B7-H3 has properties that suggested it may display antitumor activity, including the ability to stimulate Th1 and cytotoxic T-cell responses. Here, we test this notion by determining whether intratumoral injection of an expression plasmid encoding a newly described mouse homologue of B7-H3 is able to eradicate EL-4 lymphomas. Intratumoral injection of a mouse B7-H3 pcDNA3 expression plasmid led to complete regression of 50% tumors, or otherwise significantly slowed tumor growth. Mice whose tumors completely regressed resisted a challenge with parental tumor cells, indicating systemic immunity had been generated. B7-H3-mediated antitumor immunity was mediated by CD8+ T and NK cells, with no apparent contribution from CD4+ T cells. In summary, the results indicate that B7-H3 interactions may play a role in regulating cell-mediated immune responses against cancer, and that B7-H3 is a potential therapeutic tool.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Chambers CA, Allison JP . Costimulatory regulation of T cell function. Curr Opin Cell Biol 1999; 11: 203–210.

    Article  CAS  Google Scholar 

  2. Liang L, Sha WC . The right place at the right time: novel B7 family members regulate effector T cell responses. Curr Opin Immunol 2002; 14: 384–390.

    Article  CAS  Google Scholar 

  3. Coyle A, Gutierrez-Ramos J . The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001; 2: 203–209.

    Article  CAS  Google Scholar 

  4. Henry J, Miller M, Pontarotti P . Structure and evolution of the extended B7 family. Immunol Today 1999; 20: 285–288.

    Article  CAS  Google Scholar 

  5. Yoshinaga SK et al. T cell co-stimulation through B7RP-1 and ICOS. Nature 1999; 402: 827–831.

    Article  CAS  Google Scholar 

  6. Hutloff A et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397: 263–266.

    Article  CAS  Google Scholar 

  7. Freeman G et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027–1034.

    Article  CAS  Google Scholar 

  8. Latchman Y et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261–268.

    Article  CAS  Google Scholar 

  9. Tseng SY et al. B7-DC a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193: 839–846.

    Article  CAS  Google Scholar 

  10. Nishimura H et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141–151.

    Article  CAS  Google Scholar 

  11. Nishimura H et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291: 319–322.

    Article  CAS  Google Scholar 

  12. Chapoval A et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001; 2: 269–274.

    Article  CAS  Google Scholar 

  13. Townsend SE, Allison JP . Tumor rejection after direct costimulation of CD8+ T cells by B7 transfected melanoma cells. Science 1993; 259: 368–370.

    Article  CAS  Google Scholar 

  14. Chen L et al. Costimulation of anti-tumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093–1102.

    Article  CAS  Google Scholar 

  15. Baskar S et al. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated MHC class II molecules. Proc Natl Acad Sci USA 1993; 90: 5687–5690.

    Article  CAS  Google Scholar 

  16. Kanwar J, Berg R, Lehnert K, Krissansen GW . Taking lessons from dendritic cells: multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity. Gene Therapy 1999; 6: 1835–1844.

    Article  CAS  Google Scholar 

  17. Sun X et al. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Therapy 2001; 8: 638–645.

    Article  CAS  Google Scholar 

  18. Sun X et al. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. Cancer Gene Therapy 2001; 8: 719–727.

    Article  CAS  Google Scholar 

  19. Kanwar JR, Shen WP, Berg R, Krissansen GW . Effect of survivin antagonists on the growth of established tumors and B7.1 immunogene therapy. J Natl Cancer Inst 2001; 93: 1541–1552.

    Article  CAS  Google Scholar 

  20. Kanwar JR et al. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1-mediated immunotherapy overcomes immune-resistance and leads to the eradication of large tumors. Cancer Res 2000; 61: 1948–1956.

    Google Scholar 

  21. Sun M et al. Characterization of mouse and human B7-H3 genes. J Immunol 2002; 168: 6294–6297.

    Article  CAS  Google Scholar 

  22. Chen L et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179: 523–532.

    Article  CAS  Google Scholar 

  23. Maeda H, Shiraishi A . TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 1996; 156: 73–78.

    CAS  PubMed  Google Scholar 

  24. Won J et al. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy. Cancer Res 1999; 59: 1273–1277.

    CAS  PubMed  Google Scholar 

  25. Tannenbaum CS, Hamilton TA . Immune-inflammatory mechanisms in IFNgamma-mediated antitumor activity. Sem Cancer Biol 2000; 10: 113–123.

    Article  CAS  Google Scholar 

  26. Wilson JL et al. NK cell triggering by the human costimulatory molecules CD80 and CD86. J Immunol 1999; 163: 4207–4212.

    CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grants from The Wellcome Trust, the Royal Society of New Zealand, the Health Research Council of New Zealand, and the Maurice and Phyllis Paykel Trust. XS and MV contributed equally to the work. XS is a recipient of a Wellcome Trust Research Leave Fellowship. MV was a recipient of an HRC Junior Award in Health Research.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sun, X., Vale, M., Leung, E. et al. Mouse B7-H3 induces antitumor immunity. Gene Ther 10, 1728–1734 (2003). https://doi.org/10.1038/sj.gt.3302070

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302070

Keywords

This article is cited by

Search

Quick links